Results 221 to 230 of about 214,979 (267)
Some of the next articles are maybe not open access.
COPD-Lite, COPD-Hard, or COPD-for-What?
American Journal of Respiratory and Critical Care Medicine, 2011not ...
de Marco R, Accordini S, Marcon A
openaire +1 more source
Wiener Medizinische Wochenschrift, 2005
Lung function testing (spirometry) is crucial for the diagnosis of COPD, as irreversible airway obstruction is the main feature of chronic airway inflammation. Spirometry not only is essential in making the diagnosis but also in grading the disease according to FEV1 measurements.
Sylvia, Hartl, Otto C, Burghuber
openaire +2 more sources
Lung function testing (spirometry) is crucial for the diagnosis of COPD, as irreversible airway obstruction is the main feature of chronic airway inflammation. Spirometry not only is essential in making the diagnosis but also in grading the disease according to FEV1 measurements.
Sylvia, Hartl, Otto C, Burghuber
openaire +2 more sources
Clinics in Chest Medicine, 2014
Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease that cannot be described by the severity of airflow limitation (forced expiratory volume in the first second of expiration) only. Other measures are needed in clinical practice to assess patients, predict their risk, guide their treatment, and assess their response to it.
Alvar, Agusti, Don D, Sin
openaire +2 more sources
Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease that cannot be described by the severity of airflow limitation (forced expiratory volume in the first second of expiration) only. Other measures are needed in clinical practice to assess patients, predict their risk, guide their treatment, and assess their response to it.
Alvar, Agusti, Don D, Sin
openaire +2 more sources
COPD is not COPD is not ALLERGY
Wiener klinische Wochenschrift, 2009Chronic obstructive pulmonary disease (COPD) is still a poorly understood disease. Its pathogenesis is excitingly complex and has systemic consequences caused not only by increased production of certain cytokines but also by neurohumoral activation, chronic bacterial infection, muscle wasting and cachexia. Asthma and COPD have many overlapping clinical
openaire +2 more sources
Nursing Standard, 2015
Essential facts Chronic obstructive pulmonary disease (COPD) covers a number of lung conditions, including emphysema and chronic bronchitis. People with COPD have lung damage that is not fully reversible. These conditions kill about 30,000 people a year in the UK.
openaire +2 more sources
Essential facts Chronic obstructive pulmonary disease (COPD) covers a number of lung conditions, including emphysema and chronic bronchitis. People with COPD have lung damage that is not fully reversible. These conditions kill about 30,000 people a year in the UK.
openaire +2 more sources
AJN, American Journal of Nursing, 2013
Chronic obstructive pulmonary disease (COPD) is the third leading cause of death in the United States. It's estimated that more than 13 million U.S. adults have COPD, and as many as 24 million have evidence of impaired lung function, suggesting that COPD is underdiagnosed.
Leah, Burt, Susan, Corbridge
openaire +2 more sources
Chronic obstructive pulmonary disease (COPD) is the third leading cause of death in the United States. It's estimated that more than 13 million U.S. adults have COPD, and as many as 24 million have evidence of impaired lung function, suggesting that COPD is underdiagnosed.
Leah, Burt, Susan, Corbridge
openaire +2 more sources
Drug and Therapeutics Bulletin, 2012
▼Indacaterol powder for inhalation (Onbrez Breezhaler – Novartis) is a long-acting beta2 agonist, licensed for once-daily use as maintenance bronchodilator therapy for chronic obstructive pulmonary disease (COPD). In this article, we consider the evidence for indacaterol and how its use fits with current management strategies for COPD.
openaire +2 more sources
▼Indacaterol powder for inhalation (Onbrez Breezhaler – Novartis) is a long-acting beta2 agonist, licensed for once-daily use as maintenance bronchodilator therapy for chronic obstructive pulmonary disease (COPD). In this article, we consider the evidence for indacaterol and how its use fits with current management strategies for COPD.
openaire +2 more sources
Chest, 2002
In the last 200 years or so, the recognition, diagnosis, and understanding of the pathogenesis of COPD have evolved considerably. Over the past few decades, various definitions of COPD and its "components" also have developed. Despite this, however, the treatment options for patients with this relentlessly progressive disorder are relatively limited ...
openaire +2 more sources
In the last 200 years or so, the recognition, diagnosis, and understanding of the pathogenesis of COPD have evolved considerably. Over the past few decades, various definitions of COPD and its "components" also have developed. Despite this, however, the treatment options for patients with this relentlessly progressive disorder are relatively limited ...
openaire +2 more sources